Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer

Gynecologic Oncology

Volumn 126, Issue 1, 2012, Pages 54-57

  Grabowski, Jacek P ^a,b   Harter, Philipp ^a,b   Hils, Rita ^b   Lorenz, Dietmar ^b   Kaub, Christine ^b   Barinoff, Jana ^a,b   Heitz, Florian ^a,b   Traut, Alexander ^a,b   Du Bois, Andreas ^a,b  

^a KLINIKEN ESSEN MITTE   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Cytoreductive surgery; Interval debulking surgery; Primary ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL SURGERY; ADULT; AGED; ARTICLE; BLADDER SURGERY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SURGERY; CHOLECYSTECTOMY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYSTERECTOMY; INTESTINE RESECTION; LAPAROSCOPY; MORBIDITY; OMENTECTOMY; OVARY CARCINOMA; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PHYSICIAN SELF-REFERRAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REOPERATION; SMALL INTESTINE RESECTION; SPLENECTOMY; TREATMENT OUTCOME; URETER SURGERY;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; REOPERATION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84862754523     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.03.044     Document Type: Article

References (25)

1. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45:931-91.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95(Suppl. 1):S161-92.
4. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59. (Pubitemid 34177431)
5. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234-44.
6. Harter P, Muallem MZ, Buhrmann C, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 2011;121:615-9.
7. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol Oncol 2009;112:422-36.
8. Bristow RE, Zahurak ML, Diaz-Montes TP, et al. Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomes. Gynecol Oncol 2009;115:334-8.
9. Kommoss S, Rochon J, Harter P, et al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol 2010;17:279-86.
10. du Bois A, Rochon J, Lamparter C, Pfisterer J. Die Qualität der Therapie des Ovarialkarzinoms in Deutschland - Dritte Stufe der Qualitätssicherungserhebung QS-OVAR der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Kommission OVAR. Frauenarzt 2009;9:742-51.
11. Rochon J, du Bois A. Clinical research in epithelial ovarian cancer and patients' outcome. Ann Oncol 2011;22(Suppl. 7):vii16-9.
12. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.
13. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103-8. (Pubitemid 28246994)
14. Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg 2009;208:614-20.
15. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114:26-31.
16. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006;103:1083-90. (Pubitemid 44821338)
17. Harter P, Hilpert F,Mahner S, et al. Prognostic factors for complete debulking in firstand second-line ovarian cancer. Int J Gynecol Cancer 2009;19(Suppl. 2):14-7.
18. Sehouli J, Savvatis K, Braicu EI, et al. Primary versus interval debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer 2010;20:1331-40.
19. Weide R, Arndt M, Pandorf A, et al. Ovarian cancer treatment reality in northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as a possible cause for inferior survival. Onkologie 2007;30:611-7. (Pubitemid 350247759)
20. Gultekin M, Dursun P, Doǧan NU, et al. Debulking surgery for incompletely operated advanced epithelial ovarian carcinoma. J Surg Oncol 2009;100:258-60.
21. Oksefjell H, Sandstad B, Trope C. Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival. Eur J Gynaecol Oncol 2006;27:209-14. (Pubitemid 43953412)
22. Scholz HS, Tasdemir H, Hunlich T, et al. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol 2007;106:591-5. (Pubitemid 47302481)
23. Polterauer S, Vergote I, Concin N, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer international FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer 2012;22:380-5.
24. Goff BA, Matthews BJ, Larson EH, et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 2007;109:2031-42. (Pubitemid 46744198)
25. Grabowski JP, Harter P, Buhrmann C, et al. Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery. Surg Oncol 2012;21:31-5.